Innate Pharma
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Innate Pharma and buy or sell other stocks, ETFs, and their options commission-free!About IPHA
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62.
CEOJonathan Dickinson
CEOJonathan Dickinson
Employees181
Employees181
HeadquartersMarseille, Provence-Alpes-Cote-dAzur
HeadquartersMarseille, Provence-Alpes-Cote-dAzur
Founded1999
Founded1999
Employees181
Employees181
IPHA Key Statistics
Market cap181.57M
Market cap181.57M
Price-Earnings ratio-3.30
Price-Earnings ratio-3.30
Dividend yield—
Dividend yield—
Average volume35.82K
Average volume35.82K
High today$2.02
High today$2.02
Low today$1.95
Low today$1.95
Open price$1.99
Open price$1.99
Volume38.21K
Volume38.21K
52 Week high$3.51
52 Week high$3.51
52 Week low$1.29
52 Week low$1.29
IPHA News
TipRanks 3d
Innate Pharma upgraded to Buy from Neutral at H.C. WainwrightH.C. Wainwright upgraded Innate Pharma (IPHA) to Buy from Neutral with a $5 price target The company announced its intention to file an application with the FDA...
Analyst ratings
67%
of 6 ratingsBuy
66.7%
Hold
33.3%
Sell
0%